Trump Administration Considers Temporary Path for Sale of Certain Peptides

The Trump administration is considering a temporary pathway that could allow certain currently unapproved peptides to be sold through compounding pharmacies while new regulations are developed.
According to The Washington Post, the FDA has discussed using interim enforcement discretion to permit access to a limited group of peptides under specific conditions.
The proposal could include requirements around patient disclosures, adverse-event reporting and tighter oversight of how the products are distributed.
Peptides have rapidly grown in popularity across weight loss, recovery and wellness markets, but many products currently sold online lack FDA approval and rigorous clinical testing.
Supporters argue that creating a regulated temporary pathway could shift demand away from the existing gray market.
Critics, including some FDA scientists and medical experts, remain concerned that broader access could expose patients to products without sufficient evidence on safety or effectiveness.
The final policy has not yet been decided, making this an important regulatory development to watch for compounding pharmacies and digital healthcare platforms offering peptide-based treatments.